Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 11, 2026 |
| Cerevel Therapeutics Holdings, Inc.CERE · Entity 15182 | President | February 06, 2023 | February 08, 2023 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | September 04, 2025 | September 08, 2025 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director · Chief Executive Officer | October 06, 2026 | October 08, 2026 |
| scPharmaceuticals Inc.SCPH · Entity 74456 | Chief Operating Officer | January 17, 2018 | January 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,384 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 2,384 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
Cerevel Therapeutics Holdings, Inc.
Report date February 06, 2023 · Filed February 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.41 · Expires 2033-02-06 | Direct | 114,445 |
Reported balance
After 2023-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-06 · Grant · Acquired 114,445 · Balance 114,445 F1: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,083 |
Reported balance
After 2023-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-06 · Grant · Acquired 29,083 · Balance 29,083 F2: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.
Pacira BioSciences, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,039 |
Reported balance
After 2025-09-04 transaction · row 1
1 source rowRow 1 · 2025-09-04 · Sale · Disposed 2,354 · Balance 9,039 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Rapport Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 452,245 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Sale · Disposed 3,375 · Balance 453,392 F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-10-07 · Sale · Disposed 1,147 · Balance 452,245 F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Ceesay Family Irrevocable Trust | 81,729 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 81,729 |
| Common StockSEC Table I · non-derivative | IndirectBy Dorothy Ceesay Irrevocable Trust | 20,729 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 20,729 |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
scPharmaceuticals Inc.
Report date January 17, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2028-01-17 | Direct | 80,971 |
Reported balance
After 2018-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-17 · Grant · Acquired 80,971 · Balance 80,971 F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 4, 2025 22:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 428,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000950170-25-013751 · ownership.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,000 Underlying: Common Stock · 428,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000079 · wk-form4_1718316820.xml · derivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000079 · wk-form4_1718316820.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,230 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:39 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 530,647 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071533 · ownership.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,647 Underlying: Common Stock · 530,647 shares Expires 2034-06-05 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 20:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,967 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001396814-23-000070 · wk-form4_1697057179.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,967 Underlying: Common Stock · 30,967 shares Expires 2033-10-06 F1 · derivative.exercise_date: The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 29,083 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004363 · doc4.xml · derivative · entry 2 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,083 Underlying: Common Stock · 29,083 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 114,445 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0000899243-23-004363 · doc4.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,445 Underlying: Common Stock · 114,445 shares Expires 2033-02-06 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,210 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-030798 · doc4.xml · derivative · entry 3 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,009 Underlying: Common Stock · 19,210 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 19,210 | $32.50 | $624,325.00 |
DisclosureSEC source: 0000899243-22-030798 · doc4.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 19,210 | $13.17 | $252,995.70 |
DisclosureSEC source: 0000899243-22-030798 · doc4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,605 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-029606 · doc4.xml · derivative · entry 3 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,219 Underlying: Common Stock · 9,605 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 9,605 | $32.50 | $312,162.50 |
DisclosureSEC source: 0000899243-22-029606 · doc4.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 9,605 | $13.17 | $126,497.85 |
DisclosureSEC source: 0000899243-22-029606 · doc4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,606 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-028978 · doc4.xml · derivative · entry 3 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,824 Underlying: Common Stock · 9,606 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 9,606 | $34.12 | $327,756.72 |
DisclosureSEC source: 0000899243-22-028978 · doc4.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 9,606 | $13.17 | $126,511.02 |
DisclosureSEC source: 0000899243-22-028978 · doc4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,211 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · derivative · entry 7 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,430 Underlying: Common Stock · 19,211 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 9,605 | $39.50 | $379,397.50 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · nonDerivative · entry 5 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 9,606 | $37.75 | $362,626.50 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 19,211 | $13.17 | $253,008.87 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,424 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · derivative · entry 6 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,641 Underlying: Common Stock · 38,424 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 38,424 | $32.50 | $1,248,780.00 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.51. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 38,424 | $13.17 | $506,044.08 |
DisclosureSEC source: 0000899243-22-028178 · doc4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:46 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 120,310 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005940 · doc4.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,310 Underlying: Common Stock · 120,310 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 461,065 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-21-021786 · doc4.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,065 Underlying: Common Stock · 461,065 shares Expires 2031-06-01 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 16:25 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 80,971 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0000899243-18-001522 · doc4.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,971 Underlying: Common Stock · 80,971 shares Expires 2028-01-17 F1 · derivative.exercise_date: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.